Compile Data Set for Download or QSAR
Report error Found 102 Enz. Inhib. hit(s) with all data for entry = 12654
TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataKd:  300nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataKd:  300nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717813(1-(1-(2,6-difluorobenzyl)-1H-pyrrol-3-yl)-2-phenyl...)
Affinity DataKd: >500nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717814(1-(5-(2-fluorobenzoyl)-1-methyl-1H-pyrrol-2-yl)-2-...)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717815(1-(5-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataKd: >500nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717816(4-(2-fluorobenzoyl)-1-methyl-1H-pyrrole-2-carboxyl...)
Affinity DataKd: >500nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717817(1-(5-(2-fluorobenzoyl)-1-methyl-1H-pyrrol-3-yl)-2-...)
Affinity DataKd: >500nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717818(1-(1-methyl-5-picolinoyl-1H-pyrrol-2-yl)-2-phenyle...)
Affinity DataKd:  300nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717819((4-(2-fluorobenzoyl)-1-methyl-1H-pyrrol-2-yl) (8-o...)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717820((R)—N-(1-(4-(2-fluorobenzoyl)-1-methyl-1H-pyrrole-...)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717821((5-(2-fluorobenzoyl)-1-methyl-1H-pyrrol-2-yl) (8-o...)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717822(N-(tert-butyl)-5-(2-fluorobenzoyl)-1-methyl-1H-pyr...)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717823(US20250042850, Compound 5)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717824(US20250042850, Compound 9)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717825(US20250042850, Compound 10)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717826(US20250042850, Compound 13)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717827(US20250042850, Compound 14)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717828(US20250042850, Compound 16)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717829(US20250042850, Compound 20)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717830(US20250042850, Compound 21)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717831(US20250042850, Compound 26)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717832(US20250042850, Compound 23)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717833(US20250042850, Compound 24)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetPantetheinase(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717834(US20250042850, Compound 27)
Affinity DataKd: <100nMAssay Description:Table 1 and 5: Test compounds were prepared as 111X stocks in 100% DMSO. Kd values were determined using an 11-point 3-fold compound dilution series ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataIC50: 1.53E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataIC50: 2.70E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataIC50: 5.06E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717828(US20250042850, Compound 16)
Affinity DataIC50: 5.52E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717827(US20250042850, Compound 14)
Affinity DataIC50: 5.83E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717831(US20250042850, Compound 26)
Affinity DataIC50: 5.92E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717823(US20250042850, Compound 5)
Affinity DataIC50: 6.03E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717830(US20250042850, Compound 21)
Affinity DataIC50: 6.10E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717825(US20250042850, Compound 10)
Affinity DataIC50: 6.26E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataIC50: 6.34E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C8(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataIC50: 6.55E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717824(US20250042850, Compound 9)
Affinity DataIC50: 6.72E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717829(US20250042850, Compound 20)
Affinity DataIC50: 7.13E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717826(US20250042850, Compound 13)
Affinity DataIC50: 7.19E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataIC50: 7.37E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717833(US20250042850, Compound 24)
Affinity DataIC50: 7.53E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717832(US20250042850, Compound 23)
Affinity DataIC50: 8.09E+4nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C8(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717811(1-(1-(2-fluorobenzoyl)-1H-pyrrol-3-yl)-2-phenyleth...)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717812(US20250042850, Compound 2)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717823(US20250042850, Compound 5)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C8(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717823(US20250042850, Compound 5)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Athos Therapeutics

US Patent
LigandPNGBDBM717823(US20250042850, Compound 5)
Affinity DataIC50: 1.00E+5nMAssay Description:Table 3 and 4: The cocktail was incubated in human liver microsome with NADPH regenerating system (NRS) in a shaking bath at 37±2° C. The formation o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/12/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 102 total ) | Next | Last >>
Jump to: